Isocitrate Dehydrogenase Inhibitors Market Share 2022: Global Trends, Key Players, Industry Analysis Report to 2028

The Isocitrate Dehydrogenase Inhibitors Market size is expected to grow at an annual average of 4% during 2022-2028. Isocitrate dehydrogenase (IDH) is an enzyme involved in the conversion of isocitrate to -ketoglutarate in the tricarboxylic acid cycle. In the two-step reaction, IDH plays an important role in catalyzing the reversible conversion of isocitrate to alpha-ketoglutarate and CO2. IDH inhibitors are classified as IDH1 inhibitors, IDH2 inhibitors, or IDH1/IDH2 inhibitors. Agios discovered the first IDH1 inhibitor, AGI-5918, and the IDH2 inhibitor, AGI-6780. Clinical trials are conducted with all IDH inhibitors. IDH is a small molecule protein found primarily in the liver, heart muscle, and skeletal muscle.

The following segmentation are covered in this report:

By Application

• FLT3 Inhibitor
• DH Inhibitor
• Hedgehog Pathway Inhibitor
• Others

By Type

• IDH1 Mutant Medullary Malignant Tumor
• IDH2 Mutant Medullary Malignant Tumor
• Others

Company Profile

• Agios Pharmaceuticals
• Bayer
• Daiichi Sankyo Company
• Evotec
• GlaxoSmithKline
• Novartis

Scope of the report

The research study analyses the Isocitrate Dehydrogenase Inhibitors Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by Isocitrate Dehydrogenase Inhibitors Market Report

• What was the Isocitrate Dehydrogenase Inhibitors Market size in 2022 and 2028; what are the estimated growth trends and market forecast (2022-2028)
• What will be the CAGR of Market during the forecast period (2022-2028)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
• Which manufacturer/vendor/players in the Isocitrate Dehydrogenase Inhibitors Market was the market leader in 2022?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.